Do you want to read an article? Please log in or register.
Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis
Aging and Cognitive FunctionsMultiple Sclerosis
RECOMMENDED
Related content
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol.
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.
doi: 10.1001/
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
Multiple Sclerosis
Long-term disability progression in primary progressive multiple sclerosis: a 15-year study
Brain.
Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M
doi: 10.1093/brain/awx250.
RECOMMENDED
Multiple Sclerosis
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
doi: 10.1001/jamaneurol.2018.4905.
Multiple Sclerosis
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis
Mult Scler.
Ferrè L, Mogavero A, Clarelli F, Moiola L, Sangalli F, Colombo B, Martinelli V, Comi G, Filippi M, Esposito F
doi: 10.1177/1352458520961690.
RECOMMENDED
Multiple Sclerosis
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Mult Scler.
Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, Kappos L, Rudick RA, Goyal J
doi: 10.1177/1352458519885613.
Multiple Sclerosis
Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study
J Neurol Neurosurg Psychiatry.
Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Stridh P, Kockum I, Manouchehrinia A
doi: 10.1136/jnnp-2018-319913.
Multiple Sclerosis
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Mult Scler.
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P
doi: 10.1177/1352458519881759.